| Full Name | Safe Transitions |
|---|---|
| Speciality | Community/behavioral Health |
| Location | 3656 Front St, Barnum, Minnesota |
| Authorized Official Name and Position | Julie Bogenholm (PRESIDENT/EXECUTIVE DIRECTOR) |
| Authorized Official Contact | 2183893291 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Safe Transitions 3656 Front St Barnum MN 55707-9651 Ph: (218) 389-3291 | Safe Transitions 3656 Front St Barnum MN 55707-9651 Ph: (218) 389-3291 |
| NPI Number | 1174781777 |
|---|---|
| Provider Enumeration Date | 05/30/2008 |
| Last Update Date | 05/30/2008 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174781777 | NPI | - | NPPES |
| A133110000 | Medicaid | MN | |
| A692467000 | Medicaid | MN | |
| A749460200 | Medicaid | MN | |
| A839497100 | Medicaid | MN | |
| A103667100 | Medicaid | MN | |
| A752922100 | Medicaid | MN | |
| A878478000 | Medicaid | MN | |
| A507612000 | Medicaid | MN | |
| A204663000 | Medicaid | MN | |
| A270437000 | Medicaid | MN | |
| A603952000 | Medicaid | MN | |
| A493493000 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 251S00000X | Community/behavioral Health | (Minnesota) | Primary |
News Archive
Caveolin-1 may be a new target for interfering with age-dependent decline in synaptic plasticity. To explore the relationship between synaptic plasticity in the aging process and changes in learning and memory, Dr. Yang Liu and coworkers from the First Affiliated Hospital, Dalian Medical University, China examined synaptophysin expression in the hippocampus, cortex and cerebellum of rats at different ages, and analyzed the association between synaptophysin expression and cognition and behaviors.
During World War II, the Soviet Red Army was forced to move their biological warfare operations out of the path of advancing Nazi troops. Among the dangerous cargo were vials of Francisella tularensis, the organism that causes tularemia and one of the world's most infectious pathogens.
Cellectricon, a leading provider of advanced cell-based screening technologies and services, will co-host a webinar with top researchers at University College London. The webinar will explore the use of primary cells as a biologically-relevant model for biomedical research, and highlight the new high-throughput techniques and phenotypic screening approaches that are used by UCL to investigate cellular processes in such cells.
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
› Verified 1 days ago